AdvaMed Testifies in U.S. Senate
WASHINGTON – Today, President and CEO Scott Whitaker of AdvaMed, the Medtech Association, testified before the U.S. Senate Committee on Finance in its hearing focused on the impact of tariffs…
Government & Legislative Affairs
Learn more about our Advocacy work.
AdvaMed Comments to OMB Deregulation RFI
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
AdvaMed, U.K. Medtech Association Call for Flexibility on Tariffs, “Regulatory Convergence”
WASHINGTON—AdvaMed, the Medtech Association, the world’s largest organization representing medtech innovators, and the Association of British HealthTech Industries (ABHI), the leading trade association for medical technology companies in the United…
Why Lifesaving Medtech Should Be Tariff-free: An Interview with AdvaMed’s CEO
AdvaMed President and CEO Scott Whitaker is leading the call for a reciprocal “zero-for-zero” tariff agreement on medtech, urging the U.S. and its trading partners to eliminate tariffs on essential,…
AdvaMed CEO Calls for “Zero for Zero” Reciprocal Tariffs on Medtech with U.S. Trading Partners
WASHINGTON – Scott Whitaker, president and CEO of AdvaMed, the Medtech Association, today called for a reciprocal “zero for zero” model with respect to tariffs among U.S. trading partners for…
Why the Administration Should Be Flexible with Medtech Tariffs to Protect Patients and Innovation
Flexibility on tariffs is critical to maintaining medtech as the backbone of the U.S. health care system and an American economic success story.
Tariffs: Understanding the Nairobi Protocol and related Customs Procedures
Learn how the Nairobi Protocol may support duty-free access for medical devices under new tariffs. Join us April 30, 2–3:30pm ET.
AdvaMed Releases “AI Policy Roadmap” to Guide Congress and Federal Agencies
Washington, D.C.—AdvaMed, the Medtech Association, today released its “AI Policy Roadmap,” a detailed policy outline for Congress and the federal agencies with jurisdiction over medtech to consider in promoting the…
Scott Whitaker Op-Ed: Tariffs Should Spare Vital U.S. MedTech Industry
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
AdvaMed® Advancements: Q1 2025 Report
AdvaMed’s Q1 2025 report focuses on tariffs, policy action, and how we’re protecting Medtech innovation.